ReviewWorld journal of gastroenterology2017
Current and future therapies for inherited cholestatic liver diseases.
Review in World journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Pooled it
- Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease.Alimentary pharmacology & therapeutics · 2020Guideline
- Genetic and clinical spectrum of progressive familial intrahepatic cholestasis type 1: novel ATP8B1 variants and genotype-phenotype correlations.European journal of pediatrics · 2026Article
- The disease burden and health-related quality of life in Chinese children with genetic cholestatic liver diseases: a cross-sectional study of progressive familial intrahepatic cholestasis and Alagille syndrome.Orphanet journal of rare diseases · 2026Article
- Molecular characterisation of the trafficking rescue of defective ABCB4 variants by roscovitine analogues.Scientific reports · 2026Article
- Early plasmapheresis in type 2 benign recurrent intrahepatic cholestasis: A case report and review of literature.World journal of hepatology · 2025Article
- Bile acids as therapeutic agents.Frontiers in pharmacology · 2025Review
- Practical Considerations for Odevixibat Treatment in Patients with Progressive Familial Intrahepatic Cholestasis: A Single-Center Case Series.Journal of clinical medicine · 2024Article
- [Clinical characteristics ofZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Article
- Identification of new correctors for traffic-defective ABCB4 variants by a high-content screening approach.Communications biology · 2024Article
- Progressive Familial Intrahepatic Cholestasis-2 Mimicking Non-accidental Injury.ACG case reports journal · 2024Article
- Therapeutic approaches for cholestatic liver diseases: the role of nitric oxide pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Challenges in pediatric inherited/metabolic liver disease: Focus on the disease spectrum, diagnosis and management of relatively common disorders.World journal of gastroenterology · 2023Review
- Genetic alterations and molecular mechanisms underlying hereditary intrahepatic cholestasis.Frontiers in pharmacology · 2023Review
- Clinical and genetic characterization of pediatric patients with progressive familial intrahepatic cholestasis type 3 (PFIC3): identification of 14 novel ABCB4 variants and review of the literatures.Orphanet journal of rare diseases · 2022Review
- ABCB4 Mutations in Adults Cause a Spectrum Cholestatic Disorder Histologically Distinct from Other Biliary Disease.Digestive diseases and sciences · 2022Article
- Case Report: A Rare HeterozygousFrontiers in medicine · 2022Article
- Induction of Bile Canaliculi-Forming Hepatocytes from Human Pluripotent Stem Cells.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Nasobiliary drainage: an effective treatment for pruritus in cholestatic liver disease.Frontline gastroenterology · 2022Article
- Bile acid indices as biomarkers for liver diseases I: Diagnostic markers.World journal of hepatology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Familial intrahepatic cholestasis (FIC) comprises a group of rare cholestatic liver diseases associated with canalicular transport defects resulting predominantly from mutations in
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.